Clinical Trial

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
Protocol Amendment History 1 change
notable Trial sites expanded: 9 -> 17 locations 2026-08-14
Trial Details
NCT Number NCT06980116
Lead Sponsor Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Conditions Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Diffuse-large B-cell Lymphoma (DLBCL), Waldenstrom's Macroglobulinemia (WM)
Enrollment 85 participants
Start Date 2025-03-31
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13